Buscar
Mostrando ítems 71-80 de 103
Artículo
Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States
(Lippincott, Williams & Wilkins, 2021-12-17)
One fifth of patients with nonalcoholic fatty liver disease (NAFLD) may progress to nonalcoholic steatohepatitis (NASH), which can increase the risk of cirrhosis, cancer, and death. To date, reported predictors of NASH ...
Artículo
Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
(Nature Publishing Group, 2022)
The main aim was to evaluate changes in urea cycle enzymes in NAFLD patients and in two preclinical animal models mimicking this entity. Seventeen liver specimens from NAFLD patients were included for immunohistochemistry ...
Artículo
A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe
(Elsevier, 2020)
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and has become an important field of biomedical inquiry. We aimed to determine whether European countries have mounted ...
Artículo
Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function
(Elsevier, 2022)
Background & Aims: Autophagy-related gene 3 (ATG3) is an enzyme mainly known for its actions in the LC3 lipidation pro cess, which is essential for autophagy. Whether ATG3 plays a role in lipid metabolism or contributes ...
Artículo
Liver stiffness accuracy by magnetic resonance elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort
(Editorial Garsi, 2023)
Objectives: to evaluate the performance of magnetic resonance elastography (MRE) to stage liver fibrosis in patients with histologically confirmed nonalcoholic fatty liver disease (NAFLD) and to assess the impact of potential ...
Artículo
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the ...
Artículo
Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study
(Elsevier BV, 2020)
Background & Aims: Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeco- nomic burden, which, coupled with rising prevalence, is a growing public health challenge. However, ...
Artículo
Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria
(Sociedad Española de Patología Digestiva, 2019)
Aim: to assess the prevalence of non-alcoholic fatty liver disease (NAFLD) in the gastroenterology outpatient clinic and describe the use of the resources accordingly. Methods: a prospective and observational study of 403 ...
Artículo
A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy
(2021-12-31)
Background: Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related ...
Artículo
A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach
(Wiley, 2022)
Background Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent condition that requires a comprehensive and coordinated response across sectors and disciplines. Aims In the absence of a multisectoral framework ...